SCHEMBL13006469

SCHEMBL13006469

c1ccc(-c2cc(-c3cccc(-n4c5ccccc5c5cnccc54)n3)cc(-c3ccc4ccc5cccc6ccc3c4c56)n2)nc1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.32
▸ MCL1 Q07820 1/20 0.32
▸ METAP1 P53582 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ MAPT P10636 1/20 0.31
▸ MAOA P21397 4/20 0.31
▸ MAOB P27338 4/20 0.31
▸ ACHE P22303 1/20 0.31
▸ HSP90AA1 P07900 2/20 0.31
▸ PRKDC P78527 1/20 0.31
▸ SLC2A1 P11166 1/20 0.31
▸ HTR2C P28335 1/20 0.31
▸ TGFBR1 P36897 3/20 0.30
▸ CCR1 P32246 2/20 0.30
▸ CCR5 P51681 2/20 0.30
▸ CCR8 P51685 2/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ ALPL P05186 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006468 0.94 HSP90AA1 (0.33) MAPK14MCL1METAP1IRAK4MAPT
SCHEMBL13006466 0.89 MAPT (0.38) MAPK14IRAK4MAPTMAOAMAOB
SCHEMBL12011852 0.87 MAPK14 (0.32) MAPK14MCL1METAP1MAPTMAOA
SCHEMBL13006431 0.87 CYP11B1 (0.37) MCL1METAP1IRAK4MAPTMAOA
SCHEMBL4561522 0.86 MAOA (0.37) MAOAMAOBACHEMKNK1MKNK2
SCHEMBL4562405 0.86 MAOA (0.37) MAOAMAOBACHEMKNK1MKNK2
SCHEMBL13006461 0.86 MAPT (0.40) MAPK14IRAK4MAPTMAOAMAOB
SCHEMBL13006448 0.85 IRAK4 (0.36) MCL1METAP1IRAK4MAPTMAOA
SCHEMBL13006418 0.85 MCL1 (0.40) MCL1IRAK4MAPTMAOAMAOB
SCHEMBL13006544 0.85 MAOA (0.31) MAOAMAOBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246351-B1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-05-06 — — EP disclosed
US-8624228-B2 Compound having pyridoindole ring structure bonded with substituted pyridyl group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2014-01-07 — — US disclosed
US-8624228-B2 Compound having pyridoindole ring structure bonded with substituted pyridyl group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2014-01-07 — — US disclosed
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co,. Ltd. (JP) 2010-12-09 — — US disclosed
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co,. Ltd. (JP) 2010-12-09 — — US disclosed
EP-2246351-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co., Ltd. (JP) 2010-11-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE KCNH3, KCNH2, PRDM9 MAPK14 3179/4885MCL1 4204/4885METAP1 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback